Published in Blood Weekly, June 19th, 2003
ThromboGenics has created, on a proprietary basis, the first stabilized and readily manufactured form of the microplasmin molecule, a recombinant DNA-derived protein, which is a truncated form of the natural human protein plasmin.
The Phase I study employed an ascending-dose, placebo-controlled, randomised, double-blind design with 59 healthy, human...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.